Search

everythinglearnresearchcommunity

for

Search:↓

Exosome Therapy for hair loss, including its results and cost. The discussion also touches on the various serums used in this therapy.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

KOSHINE826 is a new anti-hair loss and hair growth solution that claims to effectively control oil, reduce hair fall, and promote real hair growth. It targets androgenetic alopecia by inhibiting DHT and has shown promising results in clinical trials.

The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Fluridil was discussed as a hair loss treatment, with some users experiencing side effects like lethargy and chest tightness. Users also mentioned other treatments like RU58841 and finasteride, with mixed opinions on their effectiveness.

A 24-year-old is using 5% topical minoxidil once daily, 1mg finasteride daily, and a derma stamp weekly for hair thickening. Users advise patience, caution with the derma stamp, and suggest waiting longer to see significant results.

A 29 year old user's progress with topical Fin/Min and microneedling treatments to improve hair loss over the span of 4 months.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.

The conversation discusses the effectiveness of RU58841 and pyrilutamide for hair loss treatment. It seeks personal success or failure stories and scientific data on these treatments.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

New hair loss treatments like Shiseido/Replicel and Histogen were discussed, with cautious optimism about their availability by 2018. Setipiprant, Replicel, and Bimatoprost were mentioned as potential treatments expected around 2016-2017.

The conversation discusses using P5P (Vitamin B6) supplements to reduce elevated Prolactin levels and concerns about its potential effect on increasing DHT levels. The user is not currently using finasteride or any anti-androgens.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

Pyrilutimide, a treatment for hair loss; it's effectiveness compared to other treatments such as Finasteride and RU58841; and some users’ experiences with the treatment.

Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

A 29-year-old man experienced significant hair thickening at the front and top after using finasteride and microneedling for two months, as noticed by his hairdresser. He used 0.5 mg/day of finasteride orally, switched to a topical solution, and performed microneedling with a Derminator2 every 6-7 days.

An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.

GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.